Estradiol cipionate/medroxyprogesterone - Pfizer

Drug Profile

Estradiol cipionate/medroxyprogesterone - Pfizer

Alternative Names: Cyclofem; CycloProvera™; Esprova™; Estradiol cypionate/medroxyprogesterone - Pharmacia; Lunella; Lunelle™; MPA/E2C

Latest Information Update: 05 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Estradiol congeners; Estrenes; Injectable contraceptives
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 05 Feb 2015 Launched for Contraception/Pregnancy (Prevention) in Argentina and Hong Kong (IM) before February 2015
  • 05 Feb 2015 Withdrawn for Contraception/Pregnancy (Prevention) in USA, Chile and Indonesia (IM) before February 2015
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top